We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Cryoablation Shows Potential as Alternative to Partial Nephrectomy

By MedImaging International staff writers
Posted on 04 Jan 2017
Image: New research suggests cryoablation could be a safe and effective option for some patients with renal cell carcinoma (Photo courtesy of Healthtap).
Image: New research suggests cryoablation could be a safe and effective option for some patients with renal cell carcinoma (Photo courtesy of Healthtap).
Researchers from the US have presented the results of a study that suggest that CT or MRI image-guided percutaneous cryoablation could be an effective and safe first-line therapy to treat patients with T1 renal cell carcinoma.

While the current standard treatment for T1 renal cell carcinoma is partial nephrectomy, image-guided cryoablation has been used in the past 15 to 20 years as a very good alternative treatment.

The results of the study were presented at the annual Radiological Society of North America (RSNA 2016) meeting, by researchers from the Brigham & Women's Hospital (BWH; Boston, MA, USA). Image-guided cryoablation is much less invasive than partial nephrectomy and only requires the insertion of one or several needles into the tumor, and the subsequent freezing of the tumor.

The study included 285 patients with solitary renal cell carcinomas who were treated with percutaneous image-guided cryoablation. Tumors were ablated using between one and seven cryoprobes, and image guidance was provided using Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scans.

The results showed a success rate (no tumor recurrence) of 97.8% for the cryoablation treatments. The overall success rate was 99% if patients underwent a second ablation because of disease recurrence. The overall survival rates after five years and 10 years were 90% and 79% respectively. The disease-specific survival rate was 98%, and 10-year cancer-free survival was 94%.

Co-author of the study, Kemal Tuncali, MD, from the BWH, said, "A number of studies have been published looking at image-guided ablation or radio frequency ablation of kidney tumors, but all have been relatively small series. The advantage of our study is that it included a larger patient population and included intermediate and long-term follow ups."

Related Links:
Brigham & Women's Hospital

Adjustable Mobile Barrier
M-458
Diagnostic Ultrasound System
DC-80A
X-Ray Illuminator
X-Ray Viewbox Illuminators
Multi-Use Ultrasound Table
Clinton

Channels

General/Advanced Imaging

view channel
Image: Example snapshots of the photon energy density at t = 0.5, 0.7, 0.9, 1.1 nanoseconds (ns) on the y = 2.0 cm plane (Horie, S., Yajima, H., Abe, M. et al., Biomedical Engineering Letters (2026). DOI: 10.1007/s13534-026-00578-9)

AI Tool Enables Real-Time Diffuse Optical Tomography for Brain Lesion Detection

Diffuse optical tomography is a noninvasive imaging technique that uses near-infrared light to detect internal abnormalities such as cerebral hemorrhage and tumors. Its clinical utility for real-time ... Read more

Imaging IT

view channel
Image: Researchers develop a vision-language model trained on large-scale data to generate clinically relevant findings from chest computed tomography images through visual question answering (Ms. Maiko Nagao from Meijo University, Japan)

Interactive AI Tool Supports Explainable Lung Nodule Assessment

Lung cancer is a leading cause of cancer mortality, and timely characterization of pulmonary nodules on chest computed tomography (CT) is essential for directing care. Interpreting nodule morphology demands... Read more

Industry News

view channel
Image: MIM KineticID is 510(k)-pending software for dynamic PET imaging and kinetic modeling, enabling time-based radiotracer analysis for clinical and research decisions (Photo courtesy of GE Healthcare)

GE HealthCare Showcases AI-Enabled Nuclear Medicine Portfolio at SNMMI 2026

Nuclear medicine is expanding rapidly as health systems adopt theranostics and broaden access to radiopharmaceuticals, increasing demand for scalable operations and consistent diagnostic confidence.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.